NCT04666129 2025-08-17
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
Clinical Trials
6 trialsNCT01792687 2025-03-04
Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate
Aragon Pharmaceuticals, Inc.
Phase 1 Completed
NCT02578797 2023-11-09
A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study
Aragon Pharmaceuticals, Inc.
Phase 1 Completed
NCT02106507 2023-05-26
ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03551782 2022-02-25
A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Completed
NCT02924766 2020-07-20
A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)
Janssen Research & Development, LLC
Phase 1 Completed